{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T09:09:41Z","timestamp":1769936981058,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006111","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejps.2020.105632","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T20:11:56Z","timestamp":1604347916000},"page":"105632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Is intranasal administration an opportunity for direct brain delivery of lacosamide?"],"prefix":"10.1016","volume":"157","author":[{"given":"Joana","family":"Gon\u00e7alves","sequence":"first","affiliation":[]},{"given":"Gilberto","family":"Alves","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3320-9658","authenticated-orcid":false,"given":"Carla","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Carona","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-1671","authenticated-orcid":false,"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105632_bib0001","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.neuint.2018.08.007","article-title":"Pregabalin and lacosamide ameliorate paclitaxel-induced peripheral neuropathy via inhibition of JAK\/STAT signaling pathway and Notch-1 receptor","volume":"120","author":"Al-Massri","year":"2018","journal-title":"Neurochem Int"},{"key":"10.1016\/j.ejps.2020.105632_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.seizure.2018.09.013","article-title":"Status epilepticus prevention, ambulatory monitoring, early seizure detection and prediction in at-risk patients","volume":"68","author":"Amengual-Gual","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.ejps.2020.105632_bib0003","doi-asserted-by":"crossref","first-page":"019","DOI":"10.1186\/s13063-019-3695-7","article-title":"Effect of lacosamide in peripheral neuropathic pain: study protocol for a randomized, placebo-controlled, phenotype-stratified trial","volume":"20","author":"Carmland","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.ejps.2020.105632_bib0004","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40262-013-0080-7","article-title":"Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide","volume":"52","author":"Cawello","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejps.2020.105632_bib0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40261-014-0177-2","article-title":"Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial","volume":"34","author":"Cawello","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ejps.2020.105632_bib0006","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/17425255.2014.883378","article-title":"Lacosamide for the treatment of epilepsy","volume":"10","author":"de Biase","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ejps.2020.105632_bib0007","series-title":"Lacosamide Therapy and CYP2C19 Genotype Drug\u00a0: lacosamide The Cytochrome P450 Superfamily","author":"Dean","year":"2018"},{"key":"10.1016\/j.ejps.2020.105632_bib0008","unstructured":"EMA (2008) Assessment report for Vimpat - Procedure No. EMEA\/H\/C\/000863."},{"key":"10.1016\/j.ejps.2020.105632_bib0009","unstructured":"EMA (2011) Guideline on bioanalytical method validation - EMEA\/CHMP\/EWP\/192217\/2009 Rev. 1 Corr. 2**, ((CHMP) CfMPfHU ed)."},{"key":"10.1016\/j.ejps.2020.105632_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2019.107735","article-title":"Biomarkers for epileptogenesis and its treatment","volume":"167","author":"Engel","year":"2020","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.ejps.2020.105632_bib0011","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2147\/DDDT.S102500","article-title":"Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics","volume":"11","author":"Fatouh","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ejps.2020.105632_bib0012","unstructured":"FDA (2018) Bioanalytical Method Validation Guidance for Industry."},{"key":"10.1016\/j.ejps.2020.105632_bib0013","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4155\/bio-2017-0199","article-title":"Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma","volume":"10","author":"Gon\u00e7alves","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ejps.2020.105632_bib0014","first-page":"74","article-title":"Pre-Clinical Assessment of the Nose-to-Brain Delivery of Zonisamide After","volume":"37","author":"Gon\u00e7alves","year":"2020","journal-title":"Intranasal Adm."},{"key":"10.1016\/j.ejps.2020.105632_bib0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijpharm.2019.04.047","article-title":"Nose-to-brain delivery of levetiracetam after intranasal administration to mice","volume":"564","author":"Gon\u00e7alves","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejps.2020.105632_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1535-7511.2008.01273.x","article-title":"Clinical perspectives on lacosamide","volume":"9","author":"Halford","year":"2009","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.ejps.2020.105632_bib0017","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3988\/jcn.2017.13.2.138","article-title":"Neuroprotective Effect of Lacosamide on Hypoxic-Ischemic Brain Injury in Neonatal Rats","volume":"13","author":"Kim","year":"2017","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.ejps.2020.105632_bib0018","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1021\/acschemneuro.7b00084","article-title":"Evaluation of Brain Pharmacokinetic and Neuropharmacodynamic Attributes of an Antiepileptic Drug, Lacosamide, in Hepatic and Renal Impairment: preclinical Evidence","volume":"8","author":"Kumar","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.ejps.2020.105632_bib0019","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2008.03.029","article-title":"Intranasal nanoemulsion based brain targeting drug delivery system of risperidone","volume":"358","author":"Kumar","year":"2008","journal-title":"Int J Pharm"},{"issue":"Suppl 5","key":"10.1016\/j.ejps.2020.105632_bib0020","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1528-1167.2007.01302.x","article-title":"ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy","volume":"48","author":"Lazarowski","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2020.105632_bib0021","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.phrs.2019.04.031","article-title":"ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches","volume":"144","author":"Leandro","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2020.105632_bib0022","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728214.2012.709846","article-title":"Emerging treatment for chronic migraine and refractory chronic migraine","volume":"17","author":"Lionetto","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.ejps.2020.105632_bib0023","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1097\/j.pain.0000000000000555","article-title":"(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology","volume":"157","author":"Moutal","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.ejps.2020.105632_bib0024","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s13346-019-00622-5","article-title":"Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles","volume":"9","author":"Nigam","year":"2019","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.ejps.2020.105632_bib0025","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2174\/1389200217666160406120509","article-title":"Drug-metabolizing Enzymes and Efflux Transporters in Nasal Epithelium: influence on the Bioavailability of Intranasally Administered Drugs","volume":"17","author":"Oliveira","year":"2016","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ejps.2020.105632_bib0026","first-page":"473","article-title":"A new fluorometric assay for cytotoxicity measurements in-vitro","volume":"3","author":"Page","year":"1993","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejps.2020.105632_bib0027","first-page":"7","article-title":"Pluronic\u00ae block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances","volume":"5","author":"Pitto-Barry","year":"2014","journal-title":"Plolymer Chemistry"},{"key":"10.1016\/j.ejps.2020.105632_bib0028","doi-asserted-by":"crossref","first-page":"12347","DOI":"10.3390\/s120912347","article-title":"Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays","volume":"12","author":"Rampersad","year":"2012","journal-title":"Sensors"},{"key":"10.1016\/j.ejps.2020.105632_bib0029","doi-asserted-by":"crossref","first-page":"017","DOI":"10.1186\/s13046-017-0546-9","article-title":"In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells","volume":"36","author":"Rizzo","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejps.2020.105632_bib0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13318-019-00601-8","article-title":"Is Therapeutic Drug Monitoring of Lacosamide Needed in Patients with Seizures and Epilepsy?","volume":"45","author":"Schultz","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.ejps.2020.105632_bib0031","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpharm.2015.05.021","article-title":"Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice","volume":"490","author":"Serralheiro","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejps.2020.105632_bib0032","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/00207454.2015.1038710","article-title":"Intractable epilepsy and the P-glycoprotein hypothesis","volume":"126","author":"Wang","year":"2016","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.ejps.2020.105632_bib0033","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1097\/WNR.0000000000001123","article-title":"Lacosamide modulates collapsin response mediator protein 2 and inhibits mossy fiber sprouting after kainic acid-induced status epilepticus","volume":"29","author":"Wang","year":"2018","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejps.2020.105632_bib0034","first-page":"246","article-title":"Evaluation of the alamarblue assay for adherent cell irradiation experiments","volume":"12","author":"Zachari","year":"2013","journal-title":"Dose Response"},{"key":"10.1016\/j.ejps.2020.105632_bib0035","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/epi.12158","article-title":"Potential role for human P-glycoprotein in the transport of lacosamide","volume":"54","author":"Zhang","year":"2013","journal-title":"Epilepsia"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720304206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720304206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:10:58Z","timestamp":1769886658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720304206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":35,"alternative-id":["S0928098720304206"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105632","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is intranasal administration an opportunity for direct brain delivery of lacosamide?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105632"}}